Targeted Medical Pharma Introduces New Dietary Supplement Clearwayz™ for Healthy Sinus and Immune Function

 Supporting the Sinus and Immune Systems’ Anti-Inflammatory Processes   

Los Angeles, November 13, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the launch of Clearwayz, a dietary supplement specially formulated to support healthy sinus and immune function. Clearwayz is the first product in a line of dietary supplements being manufactured by AminoLabs, a division of Targeted Medical Pharma.

Clearwayz is the first oral supplement to utilize “Targeted Cellular Technology,” a patented molecular system used in our medical foods, which stimulates the rapid cellular uptake and utilization of nutrients. The proprietary formulation of polyphenols, nutrients and amino acids in Clearwayz provides the body with targeted nutrition to support the natural anti-inflammatory processes in the sinuses, as well as support a healthy immune response. Clearwayz can be purchased online at www.clearwayz.com, or by calling (888) 394-3439.

“Each ingredient in Clearwayz has been extensively researched for both safety and efficacy, and have established health benefits,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “The use of polyphenols and amino acids to address inflammation and pulmonary issues is well regarded in the medical community. Clearwayz combines these ingredients into a proprietary blend which leverages our Targeted Cellular Technology platform to provide sustained sinus, immune and pulmonary support.

About AminoLabs

Established in 2013, AminoLabs is a division of Targeted Medical Pharma Inc., which specializes in the research, development and commercialization of proprietary dietary supplements and novel delivery systems to increase uptake and improve ingredient efficacy.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I along with a line of proprietary dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #